Literature DB >> 8839607

The immunopathogenesis of multiple sclerosis and Guillain-Barré syndrome.

G Giovannoni1, H P Hartung.   

Abstract

This review covers current hypotheses regarding antigen-specific disease induction, immune responses within the central and peripheral nervous systems, the nonspecific inflammatory cascade, and mechanisms responsible for demyelination, axonal loss, and disease progression in multiple sclerosis and Guillain-Barré syndrome. We also discuss the new evidence on the role of infection as an aetiological factor in multiple sclerosis and Guillain-Barré syndrome.

Entities:  

Mesh：

Year:  1996        PMID： 8839607     DOI： 10.1097/00019052-199606000-00004

Source DB:  PubMed          Journal:  Curr Opin Neurol        ISSN： 1350-7540            Impact factor:   5.710


  9 in total

Review 1.  Management of secondary-progressive multiple sclerosis.

Authors:  Gavin Giovannoni
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

2.  Vasoactive intestinal polypeptide suppressed experimental autoimmune encephalomyelitis by inhibiting T helper 1 responses.

Authors:  Haiyan Li; Yunhua Mei; Ying Wang; Lingyun Xu
Journal:  J Clin Immunol       Date:  2006-09-10       Impact factor: 8.317

3.  A little stress is good: IFN-gamma, demyelination, and multiple sclerosis.

Authors:  Jason R Lees; Anne H Cross
Journal:  J Clin Invest       Date:  2007-02       Impact factor: 14.808

4.  Amantadine for treatment of fatigue in Guillain-Barre syndrome: a randomised, double blind, placebo controlled, crossover trial.

Authors:  M P J Garssen; P I M Schmitz; I S J Merkies; B C Jacobs; F G A van der Meché; P A van Doorn
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-01       Impact factor: 10.154

5.  Assessment of autonomic dysfunction in childhood guillain-barré syndrome.

Authors:  Mahmood Samadi; Babak Kazemi; Sona Golzari Oskoui; Mohammad Barzegar
Journal:  J Cardiovasc Thorac Res       Date:  2013-10-05

6.  IL-15 mRNA expression is up-regulated in blood and cerebrospinal fluid mononuclear cells in multiple sclerosis (MS).

Authors:  P Kivisäkk; D Matusevicius; B He; M Söderström; S Fredrikson; H Link
Journal:  Clin Exp Immunol       Date:  1998-01       Impact factor: 4.330

7.  Stem cell factor-activated bone marrow ameliorates amyotrophic lateral sclerosis by promoting protective microglial migration.

Authors:  Tomoya Terashima; Hideto Kojima; Hiroshi Urabe; Isamu Yamakawa; Nobuhiro Ogawa; Hiromichi Kawai; Lawrence Chan; Hiroshi Maegawa
Journal:  J Neurosci Res       Date:  2014-07       Impact factor: 4.164

8.  The immunoregulatory abilities of polymorphonuclear neutrophils in the course of multiple sclerosis.

Authors:  J Ziaber; J Paśnik; Z Baj; L Pokoca; H Chmielewski; H Tchórzewski
Journal:  Mediators Inflamm       Date:  1998       Impact factor: 4.711

Review 9.  Can COVID-19 pandemic boost the epidemic of neurodegenerative diseases?

Authors:  Alexei Verkhratsky; Qing Li; Sonia Melino; Gerry Melino; Yufang Shi
Journal:  Biol Direct       Date:  2020-11-27       Impact factor: 4.540
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.